Thomas G Liman1,2,3, Eberhard Siebert4, Matthias Endres1,2,3,5,6. 1. Center for Stroke Research Berlin (CSB). 2. Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin. 3. German Centre for Cardiovascular Research (DZHK). 4. Institute of Neuroradiology, Charité - Universitätsmedizin Berlin. 5. German Center for Neurodegenerative Diseases (DZNE). 6. Berlin Institute of Health (BIH), Berlin, Germany.
Abstract
PURPOSE OF REVIEW: Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological syndrome characterized by acute cerebral endotheliopathy with consecutive disruption of the blood-brain barrier and vasogenic edema. Since its first description in 1996, PRES is increasingly recognized. However, many aspects of this syndrome with its wide spectrum of clinical and radiological features are still incompletely understood. In this review, possible pathophysiological mechanisms, approaches to diagnosis, recent study results on outcome, and future directions of research are described. RECENT FINDINGS: Clinical manifestations of PRES include seizures, headache, visual disturbances, altered mental state, and more rarely hemiparesis or aphasia. Vasogenic edema predominantly occurs in the parieto-occipital region, but lesions affecting formerly called 'atypical' regions such as frontal lobe, cerebellum, or basal ganglia are common. If treated early and adequately, that is by removal of the underlying cause, PRES has a favorable prognosis, but neurological residual symptoms and even mortality can occur, particularly in patients with complications such as intracranial hemorrhage. SUMMARY: In summary, validated diagnostic criteria and algorithms are warranted to standardize the diagnosis of PRES. This is essential for further research and future prospective studies that should investigate risk factors for unfavorable outcome and identify the roles of imaging features, clinical symptoms, and other biomarkers in predicting outcome.
PURPOSE OF REVIEW: Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological syndrome characterized by acute cerebral endotheliopathy with consecutive disruption of the blood-brain barrier and vasogenic edema. Since its first description in 1996, PRES is increasingly recognized. However, many aspects of this syndrome with its wide spectrum of clinical and radiological features are still incompletely understood. In this review, possible pathophysiological mechanisms, approaches to diagnosis, recent study results on outcome, and future directions of research are described. RECENT FINDINGS: Clinical manifestations of PRES include seizures, headache, visual disturbances, altered mental state, and more rarely hemiparesis or aphasia. Vasogenic edema predominantly occurs in the parieto-occipital region, but lesions affecting formerly called 'atypical' regions such as frontal lobe, cerebellum, or basal ganglia are common. If treated early and adequately, that is by removal of the underlying cause, PRES has a favorable prognosis, but neurological residual symptoms and even mortality can occur, particularly in patients with complications such as intracranial hemorrhage. SUMMARY: In summary, validated diagnostic criteria and algorithms are warranted to standardize the diagnosis of PRES. This is essential for further research and future prospective studies that should investigate risk factors for unfavorable outcome and identify the roles of imaging features, clinical symptoms, and other biomarkers in predicting outcome.
Authors: Pria Anand; K H Vincent Lau; David Y Chung; Deepti Virmani; Anna M Cervantes-Arslanian; Asim Z Mian; Courtney E Takahashi Journal: J Stroke Cerebrovasc Dis Date: 2020-07-30 Impact factor: 2.136
Authors: Anwar J Alnass; Rahaf A Alamer; Hend H Alamri; Azzah A Alharthi; Majd A Assad; Mohammed K Al Sedran; Dunya A Bu-Izran; Bayan F Mirza; Amwaj A Almalki; Malak Alshammari Journal: Cureus Date: 2021-10-01
Authors: J J Tortajada-Soler; M P Tauler Redondo; M Garví López; M B Lozano Serrano; J López-Torres López; M L Sánchez López Journal: Rev Esp Anestesiol Reanim (Engl Ed) Date: 2021-07-30